Bioluminescence used MRI to observe the dilation of luciferase in engineered blood vessels Engineers from the Massachusetts Institute of Technology (MIT) have developed a
Medicine
MHRA’s AI Airlock to address challenges for regulating AI medical devices
The sandbox will help to inform future AI Airlock projects and influence future AlaMD guidance The Medicines and Healthcare products Regulatory Agency (MHRA) has
NHS reduces long waits for cancer care and achieves faster ambulance responses
For the second month in a row, the NHS has met the 28-day faster diagnosis target for cancer The NHS has announced, for the
OneChain’s CAR T trial treats its first cortical T-cell ALL patient
The subtype accounts for 20% of all T-cell leukaemias, a rare form of blood cancer which produces too many abnormal T-cells OneChain Immunotherapeutics (OCI),
Oregon and Lantern collaborate to develop drug candidate for various cancer indications
Anticancer drugs will be responsible for 90% of nearly 612,000 predicted US cancer deaths in 2024 Oregon Therapeutics and Lantern Pharma have entered into
Chiesi and Gossamer collaborate to develop drug to treat respiratory diseases
Gossamer’s seralutinib is designed to treat pulmonary arterial hypertension and other indications Chiesi Group and Gossamer Bio have announced a global collaboration and license
Johns Hopkins scientists depict molecular pathway to track replication in cancer cells
The findings could potentially lead to new therapies and could stop the growth of cancers Johns Hopkins Medicine scientists have revealed a molecular pathway
Francis Crick Institute and Broken String Biosciences partner for ALS research
The rare and fatal progressive neurodegenerative disease is estimated to affect 5,000 people in the UK The Francis Crick Institute and Broken String Biosciences
NHS to roll out fibre optic laser therapy to prevent seizures in epileptic patients
The chronic brain disease that causes seizures currently affects around 600,000 people living in the UK The NHS has announced that it will be
International phase 3 clinical trial for new melanoma treatment recruits first patients
The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda A phase 3 international trial evaluating a new personalised immunotherapy treatment for